Prognostic significance of triglyceride-glucose index in acute coronary syndrome patients without standard modifiable cardiovascular risk factors.

Publisher: BioMed Central Country of Publication: England NLM ID: 101147637 Publication Model: Electronic Cited Medium: Internet ISSN: 1475-2840 (Electronic) Linking ISSN: 14752840 NLM ISO Abbreviation: Cardiovasc Diabetol Subsets: MEDLINE

Original Publication: London : BioMed Central, [2002-

Acute Coronary Syndrome*/blood ; Acute Coronary Syndrome*/mortality ; Acute Coronary Syndrome*/diagnosis ; Biomarkers*/blood ; Predictive Value of Tests* ; Triglycerides*/blood ; Blood Glucose*/metabolism; Humans ; Male ; Middle Aged ; Female ; Aged ; Risk Assessment ; Prognosis ; Time Factors ; Beijing/epidemiology ; Heart Disease Risk Factors ; Retrospective Studies ; Coronary Angiography

Background: A significant percentage of patients with acute coronary syndrome (ACS) without standard modifiable cardiovascular risk factors (SMuRFs) are being identified. Nonetheless, the prognostic influence of the TyG index on adverse events in this type of patient remains unexplored. The aim of this study was to assess the prognostic value of the TyG index among ACS patients without SMuRFs for predicting adverse outcomes.
Methods: This study involved 1140 consecutive patients who were diagnosed with ACS without SMuRFs at Beijing Anzhen Hospital between May 2018 and December 2020 and underwent coronary angiography. Each patient was followed up for a period of 35 to 66 months after discharge. The objective of this study was to examine major adverse cardiac and cerebrovascular events (MACCE), which included all-cause mortality, non-fatal myocardial infarction, non-fatal ischemic stroke, as well as ischemia-driven revascularization.
Results: During the median follow-up period of 48.3 months, 220 (19.3%) MACCE events occurred. The average age of the participants was 59.55 ± 10.98 years, and the average TyG index was 8.67 ± 0.53. In the fully adjusted model, when considering the TyG index as either a continuous/categorical variable, significant associations with adverse outcomes were observed. Specifically, for each 1 standard deviation increase in the TyG index within the highest TyG index group, there was a hazard ratio (HR) of 1.245 (95% confidence interval CI 1.030, 1.504) for MACCE and 1.303 (95% CI 1.026, 1.653) for ischemia-driven revascularization (both P < 0.05), when the TyG index was analyzed as a continuous variable. Similarly, when the TyG index was examined as a categorical variable, the HR (95% CI) for MACCE in the highest TyG index group was 1.693 (95% CI 1.051, 2.727) (P < 0.05) in the fully adjusted model, while the HR (95% CI) for ischemia-driven revascularization was 1.855 (95% CI 0.998, 3.449) (P = 0.051). Additionally, the TyG index was found to be associated with a poor prognosis among the subgroup.
Conclusion: The TyG index is correlated with poor prognosis in patients with ACS without SMuRFs, suggesting that it may be an independent predictive factor of adverse events among these individuals.
(© 2024. The Author(s).)

Cardiovasc Res. 2021 May 25;117(6):e76-e78. (PMID: 34037711)
Can J Cardiol. 2015 Dec;31(12):1455-61. (PMID: 26143140)
Front Cardiovasc Med. 2022 Mar 29;9:869168. (PMID: 35425823)
Cardiovasc Diabetol. 2022 Sep 1;21(1):168. (PMID: 36050734)
Horm Metab Res. 2021 Sep;53(9):594-601. (PMID: 34298566)
Lipids Health Dis. 2022 Nov 26;21(1):126. (PMID: 36435770)
J Am Coll Cardiol. 2023 Sep 26;82(13):1343-1359. (PMID: 37730292)
Cardiovasc Diabetol. 2022 May 6;21(1):68. (PMID: 35524263)
Diabetologia. 2010 Jul;53(7):1270-87. (PMID: 20361178)
Eur Heart J Cardiovasc Imaging. 2022 Nov 17;23(12):e537-e538. (PMID: 36069116)
J Cardiol. 2022 Apr;79(4):515-521. (PMID: 34801329)
Circulation. 2022 Jan 18;145(3):e18-e114. (PMID: 34882435)
Eur Heart J. 2019 Jan 7;40(2):79-80. (PMID: 30615155)
Cardiovasc Diabetol. 2022 Jan 6;21(1):3. (PMID: 34991602)
Am J Cardiol. 2023 Sep 1;202:81-89. (PMID: 37423175)
J Int Med Res. 2023 Mar;51(3):3000605231164548. (PMID: 36994866)
Cells. 2022 Nov 30;11(23):. (PMID: 36497101)
J Am Coll Cardiol. 2023 Dec 19;82(25):2350-2473. (PMID: 38092509)
Circulation. 2018 Nov 13;138(20):e618-e651. (PMID: 30571511)
J Am Heart Assoc. 2019 Nov 5;8(21):e013296. (PMID: 31672080)
Front Cardiovasc Med. 2021 Sep 13;8:737899. (PMID: 34589530)
J Am Coll Cardiol. 2011 Aug 9;58(7):778. (PMID: 21816321)
Nutr Metab Cardiovasc Dis. 2021 Oct 28;31(11):3024-3030. (PMID: 34625361)
Am J Prev Cardiol. 2020 Nov 24;4:100116. (PMID: 34327476)
Eur J Prev Cardiol. 2017 Nov;24(17):1824-1830. (PMID: 28703626)
Arch Med Res. 2016 Jul;47(5):382-387. (PMID: 27751372)
J Diabetes. 2020 Feb;12(2):102-104. (PMID: 31411812)
Zhonghua Xin Xue Guan Bing Za Zhi. 2023 Mar 24;51(3):221-255. (PMID: 36925135)
Cardiovasc Diabetol. 2023 Jul 6;22(1):170. (PMID: 37415168)
J Atheroscler Thromb. 2022 Feb 1;29(2):268-281. (PMID: 33536384)
Eur J Prev Cardiol. 2020 Jun;27(9):988-998. (PMID: 30614262)
Front Endocrinol (Lausanne). 2022 Feb 22;13:843072. (PMID: 35295991)
Lancet. 2021 Mar 20;397(10279):1085-1094. (PMID: 33711294)
Int J Cardiol Cardiovasc Risk Prev. 2024 Feb 24;20:200250. (PMID: 38476976)
J Thromb Thrombolysis. 2022 Nov;54(4):569-578. (PMID: 36094686)
Nutr Metab Cardiovasc Dis. 2021 Oct 28;31(11):3184-3192. (PMID: 34511291)
World J Diabetes. 2019 Feb 15;10(2):63-77. (PMID: 30788044)
Cardiovasc Diabetol. 2021 Jan 12;20(1):19. (PMID: 33435964)
Nutr Metab Cardiovasc Dis. 2020 Nov 27;30(12):2351-2362. (PMID: 32917496)
Front Cardiovasc Med. 2022 Apr 07;9:824470. (PMID: 35463764)
Eur Heart J. 2021 Oct 1;42(37):3822-3824. (PMID: 34293105)
Front Cardiovasc Med. 2022 Jul 27;9:916085. (PMID: 35966532)
Circulation. 2022 Jan 18;145(3):e4-e17. (PMID: 34882436)
Exp Ther Med. 2018 Sep;16(3):2022-2026. (PMID: 30186434)
Int J Cardiol. 2023 Jan 15;371:432-440. (PMID: 36179904)
Circ Res. 2019 Jan 18;124(2):315-327. (PMID: 30653442)
Diabetol Metab Syndr. 2018 Oct 05;10:74. (PMID: 30323862)
Nat Rev Endocrinol. 2014 May;10(5):293-302. (PMID: 24663222)

2022YFC3602500 National Key Research and Development Program of China

Keywords: Acute coronary syndrome; Prognosis; Standard modifiable cardiovascular risk factors; Triglyceride glucose index

0 (Biomarkers)
0 (Triglycerides)
0 (Blood Glucose)

Date Created: 20240723 Date Completed: 20240724 Latest Revision: 20240913

20240914

PMC11267681

10.1186/s12933-024-02345-5

39044255